Rare Insulin Resistance Syndromes Show Limited Response to IGF-1 Treatment

This study examined treatment outcomes for patients with Donohue and Rabson-Mendenhall syndromes, extremely rare genetic disorders causing severe insulin resistance from birth due to mutations in the insulin receptor gene. Understanding these conditions matters because they represent the most extreme forms of insulin resistance, potentially offering insights into diabetes treatment and metabolic health optimization.

Researchers conducted a retrospective analysis of patients treated with recombinant human IGF-1 (rhIGF-1) at a single medical center, combining their data with previously published cases. The study included detailed case reviews and literature searches to compile comprehensive treatment outcome data.

The results revealed mixed and ultimately disappointing outcomes. While rhIGF-1 treatment initially provided some metabolic benefits including improved blood sugar control, better fasting tolerance, and modest growth enhancement in early childhood, these improvements were temporary. Two patients showed poor response or intolerance to treatment and died in infancy. Most concerning, the longest-surviving patients experienced progressive deterioration to full diabetes mellitus despite continuous rhIGF-1 therapy.

For longevity and metabolic health, this research underscores the complexity of insulin signaling pathways and the limitations of current therapeutic approaches. The findings suggest that even aggressive treatment with IGF-1, which bypasses some insulin resistance mechanisms, cannot fully compensate for severe insulin receptor dysfunction. This highlights the critical importance of maintaining healthy insulin sensitivity through lifestyle interventions in the general population, as therapeutic options remain limited once severe insulin resistance develops.